The MYCN oncoprotein as a drug development target.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The MYCN proto-oncogene is frequently amplified in advanced-stage cancers, notably neuroblastoma, correlating with poor prognosis.
• MYCN, a transcription factor, forms essential MYC/MAX complexes that drive cell cycle progression and transformation.
• Targeting MYCN offers a promising strategy for developing specific cancer therapies.

Purpose of the Study:

• To review MYCN as a specific target for cancer therapy.
• To describe the development and validation of a functional MYCN reporter gene assay.
• To pilot screen compound libraries using the assay to identify potential therapeutic agents.

Main Methods:

• Development of a MYCN reporter gene assay using neuroblastoma cells (NGP) transfected with a luciferase construct.
• Pilot screening of 2800 compounds from the Cancer Research-UK collection.
• Assessing compounds based on their ability to reduce MYCN-dependent luciferase activity.

Main Results:

• Five compounds demonstrated significant reduction (>50%) in MYCN-dependent luciferase activity upon repeated screening.
• The developed assay is validated for its effectiveness in identifying MYCN inhibitors.
• Established a causal link between MYCN overexpression and the transformed phenotype in neuroblastoma models.

Conclusions:

• The functional MYCN reporter gene assay is a valuable tool for high-throughput screening.
• Identified initial compounds with potential as therapeutic agents targeting MYCN.
• This approach aids in developing specific therapeutic strategies for MYCN-driven cancers.